Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • Thursday
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceGlobeNewsWire • 04/08/24
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/11/24
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsGlobeNewsWire • 03/06/24
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development CandidateGlobeNewsWire • 01/08/24
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesGlobeNewsWire • 12/05/23
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)GlobeNewsWire • 11/28/23
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 10/30/23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for PalazestrantGlobeNewsWire • 10/22/23
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of DirectorsGlobeNewsWire • 10/17/23
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO CongressGlobeNewsWire • 10/16/23
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor ActivityGlobeNewsWire • 10/12/23
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to TradeZacks Investment Research • 10/11/23
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep goingZacks Investment Research • 10/11/23
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?Zacks Investment Research • 09/25/23
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/20/23